30 Chapter 2 Table 1: Patient characteristics All Men Women Classical Non-classical Classical Non-classical General Number of patients, n (%) 213 (100%) 57 (27%) 26 (12%) 98 (46%) 32 (15%) Age at last outpatient visit or death (years), median (range) 50 (19-83) 45 (19-66) 64 (26-78) 51 (19-83) 47 (23-79) Cumulative follow up from age of 15 (years) 7090 1546 1190 3213 1140 Age at first outpatient clinic visit (years) median (range) 42 (3-77) 30 (3-58) 60 (22-70) 41 (7-71) 44 (19-77) Comorbidities Number of patients with CVA at any time, n (%) 25 (12%) 9 (16%) 5 (19%) 11 (11%) 0 (0%) Obesity†, n (%) 30/198 (15%) 1/51 (2%) 4/24 (17%) 16/93 (17%) 9/30 (30%) Smoking†, n (%) 75/177 (42%) 17/44 (39%) 14/23 (61%) 35/87 (40%) 9/23 (39%) Hypertension†, n (%) 48/199 (24%) 8/51 (16%) 11/26 (42%) 18/95 (19%) 11/27 (41%) Dyslipidemia†, n (%) 14/187 (8%) 0/43 (0%) 7/23 (30%) 5/91 (6%) 2/30 (7%) Diabetes mellitus†, n (%) 4/203 (2%) 0/52 (0%) 2/25 (8%) 1/96 (1%) 1/30 (3%) Cardiac imaging Echocardiography Available echocardiography at any time, n (%) 181 (85%) 49 (86%) 21 (81%) 87 (89%) 24 (75%) Left ventricular hypertrophy on echocardiography at any time, n (%)* 90/181 (50%) 24/49 (49%) 16/21 (76%) 43/87 (49%) 7/24 (29%) Cardiac MR** Available cardiac MR at last follow-up, n (%) 141 (66%) 41 (72%) 11 (42%) 71 (73%) 18 (56%) Left ventricular ejection fraction (%), median (range) 61 (24-84) 57 (24-70) 57 (48-67) 63 (51-84) 61 (57-70) Available cardiac MR, where myocardial fibrosis was assessed by late gadolinium enhancement, n (%) 139/141 (99%) 39/41 (95%) 11/11 (100%) 71/71 (100%) 18/18 (100%) Myocardial fibrosis on cardiac MR, n (%) 54/139 (39%) 13/39 (33%) 6/11 (55%) 29/71 (41%) 6/18 (33%)
RkJQdWJsaXNoZXIy MTk4NDMw